Your session is about to expire
← Back to Search
Etavopivat for Myelodysplastic Syndrome
Study Summary
This trial studies the safety and effectiveness of a new drug for treating anemia in adults with MDS.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I am 18 years old or older.My MDS is linked to a specific genetic change and has not been caused by previous cancer treatments.
- Group 1: Etavopivat 400 mg QD daily
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Does the study currently have openings for participants?
"Per clinicaltrials.gov, the trial is recruiting participants and was first listed on November 22nd 2022 with its most recent edit occurring December 13th of that same year."
How detrimental can the daily ingestion of Etavopivat 400mg be to individuals?
"Despite being a Phase 2 trial, meaning efficacy data is limited, there are indications that etavopivat 400 mg QD daily has some degree of safety; thus earning it an assessment score of 2."
How many participants are being accepted into this research initiative?
"Affirmative, this clinical trial is currently seeking participants. According to the information on clinicialtrials.gov, it was originally posted on November 22nd 2022 and last updated December 13th 2022. 45 candidates are needed from two different sites for enrolment in the study."
Share this study with friends
Copy Link
Messenger